{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:11:18Z","timestamp":1789665078675,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tamoxifen, which is one of the selective estrogen receptor modulators (SERMs), can bring out life-threatening complication, e.g. hypertriglyceridemia-induced acute pancreatitis, although it is rare. We precisely report changes in lipoprotein metabolism before and after tamoxifen discontinuation because there have been few reports of it.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>47-year-old premenopausal woman with dyslipidemia, type 2 diabetes, nonalcoholic fatty liver disease and chronic kidney disease was prescribed tamoxifen as adjuvant therapy after operation of breast cancer. She experienced severe tamoxifen-induced hypertriglyceridemia several months after dosing tamoxifen. Before cessation of tamoxifen, lipoprotein fraction test revealed marked stagnation of VLDL and IDL metabolisms, resulting in severe hypertriglyceridemia (serum triglyceride level was 1881\u2009mg\/dL). Seven days after tamoxifen withdrawal, lipoprotein fraction test showed that the metabolisms of endogenous lipoproteins were changed drastically.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>From these results, we confirmed that tamoxifen certainly changes lipoprotein metabolism through suppression of post-heparin lipolytic activity. It is very important to evaluate the balance between benefit and risk before dosing tamoxifen and survey lipid profiles constantly during treatment to avoid life-threatening complication when prescription of tamoxifen is planned.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00780-z","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T21:17:29Z","timestamp":1623273449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time"],"prefix":"10.1186","volume":"21","author":[{"given":"Hayato","family":"Isobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-9613","authenticated-orcid":false,"given":"Masashi","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Katakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoatsu","family":"Mune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"1","key":"780_CR1","first-page":"78","volume":"9","author":"M Heery","year":"2018","unstructured":"Heery M, Corbett P, Zelkowitz R. Precautions for patients taking tamoxifen. J Adv Pract Oncol. 2018;9(1):78\u201383.","journal-title":"J Adv Pract Oncol"},{"issue":"12","key":"780_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor- positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268\u201373. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141.","journal-title":"J Clin Oncol"},{"issue":"10","key":"780_CR3","first-page":"1409","volume":"60","author":"VC Jordan","year":"1976","unstructured":"Jordan VC. Antiestrogenic and antitumor properties of TAM in laboratory animals. Cancer Treat Rep. 1976;60(10):1409\u201319.","journal-title":"Cancer Treat Rep"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for Early Breast Cancer: An Overview of the Randomised Trials. Collaborative Group. Lancet. 1998;351:1451\u201367.","journal-title":"Lancet"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast Cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687\u2013717.","journal-title":"Lancet."},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","volume":"88","author":"Swedish Breast Cancer Cooperative Group","year":"1996","unstructured":"Swedish Breast Cancer Cooperative Group. Randomized trial of two vs. five years of adjuvant TAM for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88:1543\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"780_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","volume":"18","author":"RS Braithwaite","year":"2003","unstructured":"Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937\u201347. https:\/\/doi.org\/10.1046\/j.1525-1497.2003.20724.x.","journal-title":"J Gen Intern Med"},{"issue":"16","key":"780_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","volume":"82","author":"RR Love","year":"1990","unstructured":"Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82(16):1327\u201332. https:\/\/doi.org\/10.1093\/jnci\/82.16.1327.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"780_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/bjc.1988.248","volume":"58","author":"PF Bruning","year":"1988","unstructured":"Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58(4):497\u20139. https:\/\/doi.org\/10.1038\/bjc.1988.248.","journal-title":"Br J Cancer"},{"issue":"4","key":"780_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1634\/theoncologist.2011-0369","volume":"17","author":"WG Romero","year":"2012","unstructured":"Romero WG, Da Silva FB, Borgo MV, Bissoli NS, Gouv\u00eaa SA, Abreu GR. Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy. Oncologist. 2012;17(4):499\u2013507. https:\/\/doi.org\/10.1634\/theoncologist.2011-0369.","journal-title":"Oncologist."},{"issue":"4","key":"780_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/tbj.13279","volume":"25","author":"K Yoneyama","year":"2019","unstructured":"Yoneyama K, Nakagawa M. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia. Breast J. 2019;25(4):788\u20139. https:\/\/doi.org\/10.1111\/tbj.13279.","journal-title":"Breast J"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5551\/jat1973.25.1-2_67","volume":"25","author":"Y Mishima","year":"1997","unstructured":"Mishima Y, Ando M, Kuyama A, Ishioka T, Kibata M. A simple method for identifying particle size of low-density lipoprotein using PAG electrophoresis: comparison between LipoPhor\u2122 and LipoPrint LDL\u2122 systems. J Jpn Atheroscler Soc. 1997;25:67\u201370.","journal-title":"J Jpn Atheroscler Soc"},{"issue":"8","key":"780_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1023\/A:1008309613082","volume":"11","author":"MS Elisaf","year":"2000","unstructured":"Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol. 2000;11(8):1067\u20139. https:\/\/doi.org\/10.1023\/A:1008309613082.","journal-title":"Ann Oncol"},{"issue":"12","key":"780_CR14","first-page":"2134","volume":"90","author":"MR Fortson","year":"1995","unstructured":"Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"780_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ajg.2009.27","volume":"104","author":"W Tsuang","year":"2009","unstructured":"Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104(4):984\u201391. https:\/\/doi.org\/10.1038\/ajg.2009.27.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"780_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","volume":"25","author":"P Valdivielso","year":"2014","unstructured":"Valdivielso P, Ram\u00edrez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2014.08.008.","journal-title":"Eur J Intern Med"},{"issue":"32","key":"780_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3760\/cma.j.issn.0376-2491.2016.32.011","volume":"96","author":"WH He","year":"2016","unstructured":"He WH, Zhu Y, Zhu Y, Liu P, Zeng H, Xia L, et al. Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes. Zhonghua Yi Xue Za Zhi. 2016;96(32):2569\u201372. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2016.32.011.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"28","key":"780_CR18","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.3748\/wjg.14.4558","volume":"14","author":"LH Deng","year":"2008","unstructured":"Deng LH, Xue P, Xia Q, Yang XN, Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008;14(28):4558\u201361. https:\/\/doi.org\/10.3748\/wjg.14.4558.","journal-title":"World J Gastroenterol"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0025-7753(04)74599-6","volume":"123","author":"S Navarro","year":"2004","unstructured":"Navarro S, Cubiella J, Feu F, Zamb\u00f3n D, Fern\u00e1ndez-Cruz L, Ros E. Hypertriglyceridemic acute pancreatitis. Is its clinical course different from lithiasic acute pancreatitis? Med Cin (Barc). 2004;123:567\u201370.","journal-title":"Med Cin (Barc)"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2147\/CIA.S66690","volume":"9","author":"S Martinkovich","year":"2014","unstructured":"Martinkovich S, Shah D, Planey SL, Arnott JA. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging. 2014;9:1437\u201352. https:\/\/doi.org\/10.2147\/CIA.S66690.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"780_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1172\/JCI108677","volume":"59","author":"DM Applebaum","year":"1977","unstructured":"Applebaum DM, Goldberg AP, Pyk\u00e4list\u00f6 OJ, Brunzell JD, Hazzard WR. Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest. 1977;59(4):601\u20138. https:\/\/doi.org\/10.1172\/JCI108677.","journal-title":"J Clin Invest"},{"issue":"3","key":"780_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0022-2275(20)30144-9","volume":"43","author":"DR Jones","year":"2002","unstructured":"Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor- mediated repression of human hepatic lipase gene transcription. J Lipid Res. 2002;43(3):383\u201391. https:\/\/doi.org\/10.1016\/S0022-2275(20)30144-9.","journal-title":"J Lipid Res"},{"issue":"15","key":"780_CR23","doi-asserted-by":"publisher","first-page":"11404","DOI":"10.1074\/jbc.275.15.11404","volume":"275","author":"H Homma","year":"2000","unstructured":"Homma H, Kurachi H, Nishio Y, Takeda T, Yamamoto T, Adachi K, et al. Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. J Biol Chem. 2000;275(15):11404\u201311. https:\/\/doi.org\/10.1074\/jbc.275.15.11404.","journal-title":"J Biol Chem"},{"issue":"5","key":"780_CR24","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1042\/bst0311070","volume":"31","author":"A Zambon","year":"2003","unstructured":"Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans. 2003;31(5):1070\u20134. https:\/\/doi.org\/10.1042\/bst0311070.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"780_CR25","doi-asserted-by":"publisher","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","volume":"297","author":"H Wang","year":"2009","unstructured":"Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297(2):E271\u201388. https:\/\/doi.org\/10.1152\/ajpendo.90920.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"780_CR26","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/1097-0142(19860601)57:11<2123::AID-CNCR2820571106>3.0.CO;2-2","volume":"57","author":"LD Brun","year":"1986","unstructured":"Brun LD, Gagn\u00e9 C, Rousseau C, Moorjani S, Lupien PJ. Severe lipemia induced by tamoxifen. Cancer. 1986;57(11):2123\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19860601)57:11<2123::AID-CNCR2820571106>3.0.CO;2-2.","journal-title":"Cancer."},{"issue":"5","key":"780_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1210\/jcem.83.5.4753","volume":"83","author":"Y Hozumi","year":"1998","unstructured":"Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab. 1998;83(5):1633\u20135. https:\/\/doi.org\/10.1210\/jcem.83.5.4753.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"780_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1023\/A:1023348021773","volume":"79","author":"CL Liu","year":"2003","unstructured":"Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat. 2003;79(1):11\u20136. https:\/\/doi.org\/10.1023\/A:1023348021773.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"780_CR29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","volume":"70","author":"JD Bagdade","year":"1990","unstructured":"Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab. 1990;70(4):1132\u20135. https:\/\/doi.org\/10.1210\/jcem-70-4-1132.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"780_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF00713400","volume":"36","author":"T Engan","year":"1995","unstructured":"Engan T, Krane J, Johannessen DC, L\u00f8nning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat. 1995;36(3):287\u201397. https:\/\/doi.org\/10.1007\/BF00713400.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"780_CR31","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.1995.13.12.2900","volume":"13","author":"H Gylling","year":"1995","unstructured":"Gylling H, Pyrh\u00f6nen S, M\u00e4ntyl\u00e4 E, M\u00e4enp\u00e4\u00e4 H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol. 1995;13(12):2900\u20135. https:\/\/doi.org\/10.1200\/JCO.1995.13.12.2900.","journal-title":"J Clin Oncol"},{"key":"780_CR32","first-page":"7.1","volume-title":"Cardiology","author":"LJ Mosca","year":"2000","unstructured":"Mosca LJ. Therapy of hyperlipidemia. In: Crawford MH, DiMarco JP, editors. Cardiology. London: Mosby; 2000. p. 7.1\u20137.19."},{"issue":"6","key":"780_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1159\/000144024","volume":"28","author":"V Tsimihodimos","year":"2008","unstructured":"Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28(6):958\u201373. https:\/\/doi.org\/10.1159\/000144024.","journal-title":"Am J Nephrol"},{"issue":"1","key":"780_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0032-1306423","volume":"32","author":"H Chatrath","year":"2012","unstructured":"Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22\u20139. https:\/\/doi.org\/10.1055\/s-0032-1306423.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"780_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22(1):5. https:\/\/doi.org\/10.1007\/s11883-020-0823-5.","journal-title":"Curr Atheroscler Rep"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00780-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00780-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00780-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T21:17:45Z","timestamp":1623273465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00780-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00780-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HK received scholarship donation from Kowa pharmaceutical company Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}